The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents

被引：15

作者：

Attal, Michel ^{[1
]}

Harousseau, Jean-Luc ^{[2
]}

机构：

[1] Ctr Hosp Purpan, F-31059 Toulouse, France

[2] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France

来源：

SEMINARS IN HEMATOLOGY | 2009年 / 46卷 / 02期

关键词：

DIAGNOSED MULTIPLE-MYELOMA; PLUS THALIDOMIDE; RANDOMIZED-TRIAL; STANDARD CHEMOTHERAPY; IMPROVES SURVIVAL; ELDERLY-PATIENTS; CLINICAL-TRIAL; TRANSPLANTATION; MELPHALAN; DEXAMETHASONE;

D O I：

10.1053/j.seminhematol.2009.02.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This review discusses the initial studies concerning the role of high-dose therapy (HDT) in multiple myeloma (MM) and gives the major conclusions drawn from this "historical period." Later, current studies using new drugs for HDT (induction, conditioning regimen, consolidation, and maintenance) are described and the promising results of this strategy reported. Finally, the issue of HDT in the era of new drug regimens is discussed, as well as the necessity of designing future trials comparing HDT and new drug regimens. Semin Hematol 46:127-132. (C) 2009 Published by Elsevier Inc.

引用

页码：127 / 132

页数：6